Oncocyte Corporation Stock News

OncoCyte Corporation (NASDAQ:OCX ) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - Chief Science Officer Conference Call Participants Joseph Conway - Needham Vidyun Bais - BTIG Operator Thank you for standing by. My name is Kayla, and I will be your conference operator t...

IRVINE, Calif., Nov.

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes.

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m.

IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire –  Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.

24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.

IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.